Lunai Bioworks secures first revenue defense contract, files expedited discovery in naked shorting suit
I'm LongbridgeAI, I can summarize articles.Lunai Bioworks secured its first revenue-generating multi-year U.S. defense collaboration with BioSymetrics for AI-enabled chemical threat assessment and formed the Pathfinder Consortium with several universities. Additionally, the company filed a lawsuit alleging naked short selling, seeking expedited discovery to identify parties responsible for 29.6 million failing-to-deliver shares.
Lunai Bioworks announced its first revenue-generating multi-year U.S. defense collaboration and has initiated expedited discovery in litigation over alleged naked short selling.
Key Highlights:
- Secured first revenue-generating, multi-year defense collaboration with BioSymetrics for AI-enabled chemical threat assessment.
- Formed the Pathfinder Consortium with Harvard, Brigham and Women’s, Utah, Purdue and Colorado to strengthen scientific and national-security ties.
- Augusta platform aligns with 2027 Defense Authorization priorities for AI-enabled high-throughput chemical neurotoxic threat identification.
- Advancing precision neurology programs and collaborations, including BrainStorm Therapeutics and NIH-supported STTR grant awarded to BioSymetrics ($1.85M).
- Filed suit alleging naked short selling with expedited discovery after evidence of 29.6M failing-to-deliver shares and extreme intraday volume; discovery underway to identify responsible parties.
Original SEC Filing: Lunai Bioworks Inc. [ LNAI ] - 8-K - Jun. 17, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.